Exploring Abiraterone Combo to Treat Prostate Cancer
Friday, April 8, 2011 - 21:30
in Health & Medicine
Investigators at New Jersey's only NCI Comprehensive Cancer Center have just launched a clinical trial that explores the effects of a new type of hormone therapy in the treatment of castration-resistant prostate cancer. At focus is the investigational drug abiraterone acetate in combination with prednisone.